Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey
- PMID:26833083
- DOI: 10.1111/head.12755
Direct and Indirect Costs of Chronic and Episodic Migraine in the United States: A Web-Based Survey
Abstract
Objective: The objective of this study was to compare the societal direct and indirect costs of chronic and episodic migraine in the United States.
Background: Episodic and chronic migraine are distinguished by the frequency of headache-days. Chronic migraine has a greater overall impact on quality of life than does episodic migraine. Individuals with chronic migraine also use more healthcare resources (resulting in higher direct costs) and experience greater decreases in productivity (resulting in higher indirect costs) than those with episodic migraine as shown in the American Migraine Prevalence and Prevention (AMPP) Study.
Methods: The International Burden of Migraine Study utilized a web-based questionnaire to elicit data on several topics related to the burden of migraine illness, including health resource utilization and productivity losses. Potential survey participants were identified by Synovate Healthcare (Chicago, IL, USA) from a pool of registered panelists from various countries. The panelists were screened online to determine eligibility and to identify individuals with migraine (episodic or chronic), based on reported symptoms. Participants from the United States were divided into episodic and chronic migraine groups, based on reported headache-day per month frequency. Direct and indirect costs were estimated by applying estimated unit costs to reported headache-related productivity losses and resource use. Costs were compared between participants with episodic and chronic migraine.
Results: Mean [standard deviation] total annual cost of headache among people with chronic migraine ($8243 [$10,646]) was over three times that of episodic migraine ($2649 [$4634], P < .001). Participants with chronic migraine had significantly greater direct medical costs ($4943 [$6382]) and indirect (lost productivity) costs ($3300 [$6907]) than did participants with episodic migraine (direct, $1705 [$3591]; indirect, $943 [$2084]) (P < .001 for each). Unlike previous findings, direct medical costs constituted the majority of total headache-related costs for both chronic migraine (60.0%, $4943 of $8243) and episodic migraine (64.3%, $1705 of $2649) participants. A large portion of direct medical costs are attributable to pharmaceutical utilization among both chronic migraine (80%, $3925 of 4943) and episodic migraine (70%, $1196 of $1705) participants.
Conclusion: The results of this study build on previous results of the AMPP Study, demonstrating that headache-related direct, indirect, and total costs are significantly greater among individuals with chronic migraine than with episodic migraine in the United States.
Keywords: chronic migraine; episodic migraine; health resources; migraine; productivity.
© 2016 American Headache Society.
Similar articles
- Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, Manack A, Proskorovsky I, Gladstone J, Buse DC, Varon SF, Goadsby PJ, Blumenfeld AM.Stokes M, et al.Headache. 2011 Jul-Aug;51(7):1058-77. doi: 10.1111/j.1526-4610.2011.01945.x.Headache. 2011.PMID:21762134
- Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, Reed M, Lipton RB.Munakata J, et al.Headache. 2009 Apr;49(4):498-508. doi: 10.1111/j.1526-4610.2009.01369.x. Epub 2009 Feb 25.Headache. 2009.PMID:19245386
- Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study.Pradalier A, Auray JP, El Hasnaoui A, Alzahouri K, Dartigues JF, Duru G, Henry P, Lantéri-Minet M, Lucas C, Chazot G, Gaudin AF.Pradalier A, et al.Pharmacoeconomics. 2004;22(15):985-99. doi: 10.2165/00019053-200422150-00003.Pharmacoeconomics. 2004.PMID:15449963
- Economic burden and costs of chronic migraine.Lanteri-Minet M.Lanteri-Minet M.Curr Pain Headache Rep. 2014 Jan;18(1):385. doi: 10.1007/s11916-013-0385-0.Curr Pain Headache Rep. 2014.PMID:24338699Review.
- Burden of migraine. A review of its socioeconomic impact.Solomon GD, Price KL.Solomon GD, et al.Pharmacoeconomics. 1997;11 Suppl 1:1-10. doi: 10.2165/00019053-199700111-00003.Pharmacoeconomics. 1997.PMID:10168038Review.
Cited by
- Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.Johnston KM, Powell L, Popoff E, Harris L, Croop R, Coric V, L'Italien G.Johnston KM, et al.Clin J Pain. 2022 Nov 1;38(11):680-685. doi: 10.1097/AJP.0000000000001072.Clin J Pain. 2022.PMID:36125279Free PMC article.
- Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine.Ford JH, Foster SA, Stauffer VL, Ruff DD, Aurora SK, Versijpt J.Ford JH, et al.Patient Prefer Adherence. 2018 Nov 13;12:2413-2424. doi: 10.2147/PPA.S182563. eCollection 2018.Patient Prefer Adherence. 2018.PMID:30519007Free PMC article.
- Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.Schwedt TJ, et al.J Manag Care Spec Pharm. 2023 Oct;29(10):1119-1128. doi: 10.18553/jmcp.2023.29.10.1119.J Manag Care Spec Pharm. 2023.PMID:37776119Free PMC article.
- Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of apost-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD.Lipton RB, et al.Cephalalgia. 2021 Jan;41(1):6-16. doi: 10.1177/0333102420973994. Epub 2020 Dec 3.Cephalalgia. 2021.PMID:33269951Free PMC article.Clinical Trial.
- Long-term outcomes of occipital nerve stimulation for chronic migraine: a cohort of 53 patients.Miller S, Watkins L, Matharu M.Miller S, et al.J Headache Pain. 2016 Dec;17(1):68. doi: 10.1186/s10194-016-0659-0. Epub 2016 Jul 30.J Headache Pain. 2016.PMID:27475100Free PMC article.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical